Determination of gluten consumption in celiac disease patients on a gluten-free diet
| Autor: | Jennifer A Sealey-Voyksner, Francisco León, Matthew A. Dickason, Ciaran P. Kelly, Remedios Dominguez, Jack A. Syage, Angel Cebolla Ramirez |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Moderate to severe medicine.medical_specialty Glutens Medicine (miscellaneous) Disease Urine digestive system Gastroenterology 03 medical and health sciences Diet Gluten-Free Feces 0302 clinical medicine Internal medicine medicine Ingestion Humans Randomized Controlled Trials as Topic chemistry.chemical_classification 030109 nutrition & dietetics Nutrition and Dietetics medicine.diagnostic_test Stool test business.industry nutritional and metabolic diseases Gluten digestive system diseases Celiac Disease Observational Studies as Topic chemistry 030211 gastroenterology & hepatology Gluten free business Biomarkers Peptide Hydrolases |
| Zdroj: | The American journal of clinical nutrition. 107(2) |
| ISSN: | 1938-3207 |
| Popis: | Background Celiac disease (CD) patients adhering to a gluten-free diet (GFD) are exposed frequently to low levels of gluten that contribute to symptoms and persistent intestinal histologic damage. Objective We analyzed prior clinical data to determine how much gluten is accidentally consumed while on a GFD. The aim was to understand the range of gluten consumption for a wide distribution of CD patients. Design A meta-analysis was conducted on data from 2 different clinical programs: 1) measurements of gluten in stool and urine in CD and non-CD populations; and 2) analysis of data from trials for the investigational therapeutic latiglutenase. The stool and urine studies included controlled gluten challenges. A calibration factor was applied that allowed normal ingestion of gluten to be computed from the urine and stool measurements. From the latiglutenase trial data, a determination of gluten consumption was made by estimating how much gluten was eliminated from patients' diets due to a trial effect that led to improved histology even in the placebo group. Results The average inadvertent exposure to gluten by CD individuals on a GFD was estimated to be ∼150-400 (mean) and ∼100-150 (median) mg/d using the stool test and ∼300-400 (mean) and ∼150 (median) mg/d using the urine test. The analyses of the latiglutenase data for CD individuals with moderate to severe symptoms indicate that patients ingested significantly >200 mg/d of gluten. Conclusions These surrogate biomarkers of gluten ingestion indicate that many individuals following a GFD regularly consume sufficient gluten to trigger symptoms and perpetuate intestinal histologic damage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|